HCV Care & Guidance HCV Care & Guidance HCV Care & Guidance
                    HCV Care & Guidance
                              Practical Education and Resources
  1. Course List
Chair
faculty image
Tiffany A. Taskaya, PA-C, CCRC
  • Physician Assistant
  • Department of Hepatology
  • Beth Israel Deaconess Medical Center
  • Boston, Massachusetts
  • Now in its second year and with an expanded curriculum, HCV Care & Guidance: Practical Education and Resources continues to guide your staff in the optimal use of new direct-acting antiviral (DAA) therapies in treating your patients with chronic hepatitis C virus (HCV) infection.

    In May 2011, the FDA approved two new drugs for the treatment of chronic hepatitis C infection: boceprevir and telaprevir. These drugs, when combined with peginterferon and ribavirin, offer a new standard of care with significantly higher response rates and shorter durations of therapy compared with PEG IFN/RBV, giving new hope to HCV-infected patients.

    A free online and point-of-care program, HCV Care & Guidance includes 16 separate activities and numerous practical resources that are designed to deliver an integrated learning experience covering the clinical issues related to DAA therapy.
  • Evaluate the efficacy and safety of anti-HCV triple therapy to formulate treatment strategies that improve response while minimizing resistance in patients with chronic HCV.
  • Implement side effect and drug-drug interaction management strategies to promote adherence and wellness in HCV-infected patients treated with triple therapy.
  • Identify and address the needs of special populations of patients with chronic HCV infection, including African Americans, substance users, and HIV/HCV coinfection.
  • Analyze the significance of predictors of response, including IL28B genotype, fibrosis stage, and prior response to interferon-based therapy.
  • Discuss the impact of resource scarcity on treatment decisions and potential strategies to increase allocation of services for care.
  • Target Audience

    These CME/CE activities have been designed for nurses, nurse practitioners, physician assistants, hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, internists, family medicine physicians, and pharmacists involved in the care of patients with HCV.

     

    Activity Goal

    The goal of these activities is to address the needs of nurse practitioners, physician assistants, hepatologists, gastroenterologists, and pharmacists for information and practical instruction regarding new direct-acting antiviral (DAA) therapies for hepatitis C and their integration into clinical practice.